Gordian Capital Singapore Pte Ltd Has $1.87 Million Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Gordian Capital Singapore Pte Ltd increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 165.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,700 shares of the medical instruments supplier's stock after acquiring an additional 3,555 shares during the period. West Pharmaceutical Services makes up approximately 0.9% of Gordian Capital Singapore Pte Ltd's portfolio, making the stock its 23rd biggest holding. Gordian Capital Singapore Pte Ltd's holdings in West Pharmaceutical Services were worth $1,867,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in shares of West Pharmaceutical Services by 6.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,449,811 shares of the medical instruments supplier's stock valued at $1,130,020,000 after acquiring an additional 203,198 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in shares of West Pharmaceutical Services by 1.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,110,903 shares of the medical instruments supplier's stock valued at $1,019,007,000 after acquiring an additional 44,376 shares in the last quarter. Brown Advisory Inc. lifted its position in shares of West Pharmaceutical Services by 11.7% in the fourth quarter. Brown Advisory Inc. now owns 2,552,036 shares of the medical instruments supplier's stock valued at $835,945,000 after acquiring an additional 266,488 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of West Pharmaceutical Services by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 1,778,940 shares of the medical instruments supplier's stock valued at $581,209,000 after acquiring an additional 38,757 shares in the last quarter. Finally, FMR LLC lifted its position in shares of West Pharmaceutical Services by 83.1% in the fourth quarter. FMR LLC now owns 1,090,603 shares of the medical instruments supplier's stock valued at $357,238,000 after acquiring an additional 494,828 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company's stock.

Analyst Upgrades and Downgrades

WST has been the topic of several recent analyst reports. Wall Street Zen downgraded West Pharmaceutical Services from a "buy" rating to a "hold" rating in a research report on Thursday, February 27th. KeyCorp reduced their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Stephens upgraded West Pharmaceutical Services to a "strong-buy" rating in a research report on Monday, April 21st. Citigroup restated a "buy" rating on shares of West Pharmaceutical Services in a research note on Thursday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 target price for the company in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $332.50.

West Pharmaceutical Services Stock Performance

NYSE:WST traded up $4.80 during trading hours on Tuesday, reaching $210.39. 184,757 shares of the stock were exchanged, compared to its average volume of 725,463. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08. The firm has a 50 day simple moving average of $212.63 and a 200-day simple moving average of $269.89. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $352.33. The stock has a market capitalization of $15.12 billion, a P/E ratio of 31.41, a P/E/G ratio of 6.74 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.23. The business had revenue of $698.00 million for the quarter, compared to the consensus estimate of $685.24 million. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The business's revenue was up .4% on a year-over-year basis. During the same quarter last year, the business posted $1.56 EPS. As a group, sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 13.19%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.